Variable | Derivation group (n = 141) | Validation group (n = 88) | p values |
---|---|---|---|
Age (year)a | 65.0 (62.0–69.0) | 67.0 (64.0–70.0) | 0.097 |
PSA (ng/mL)a | 9.00 (6.30–14.12) | 8.76 (6.31–13.69) | 0.735 |
Prostate volume (mL)a | 34.0 (26.0–49.0) | 39.0 (30.0–46.0) | 0.124 |
PSADa | 0.28 (0.16–0.45) | 0.23 (0.17–0.38) | 0.124 |
PI-RADS (%) | Â | Â | 0.505 |
 2 | 1.4 (2/141) | 0.0 (0/88) |  |
 3 | 10.6 (15/141) | 10.2 (9/88) |  |
 4 | 44.7 (63/141) | 52.3 (46/88) |  |
 5 | 43.3 (61/141) | 37.5 (33/88) |  |
Clinical T stage (%) | Â | Â | 0.383 |
 T1 | 2.8 (4/141) | 0.0 (0/88) |  |
 T2 | 73.8 (104/141) | 76.1 (67/88) |  |
 T3 | 23.4 (33/141) | 23.9 (21/88) |  |
ISUP grade (%) | Â | Â | 0.816 |
 1 | 12.8 (18/141) | 14.8 (13/88) |  |
 2 | 34.0 (48/141) | 29.5 (26/88) |  |
 3 | 29.1 (41/141) | 26.1 (23/88) |  |
 4 | 11.3 (16/141) | 15.8 (14/88) |  |
 5 | 12.8 (18/141) | 13.6 (12/88) |  |
Positive surgical margin (%) | 29.8 (42/141) | 36.4 (32/88) | 0.374 |